Pacific Biosciences of California Company Profile (NASDAQ:PACB)

About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:PACB
  • CUSIP: 69404D10
  • Web: www.pacb.com
Capitalization:
  • Market Cap: $342.39 million
  • Outstanding Shares: 93,550,000
Average Prices:
  • 50 Day Moving Avg: $4.31
  • 200 Day Moving Avg: $5.16
  • 52 Week Range: $3.64 - $10.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.38
  • P/E Growth: -0.14
Sales & Book Value:
  • Annual Revenue: $96.5 million
  • Price / Sales: 3.55
  • Book Value: $0.74 per share
  • Price / Book: 4.95
Profitability:
  • EBIDTA: ($70,100,000.00)
  • Net Margins: -81.99%
  • Return on Equity: -75.50%
  • Return on Assets: -49.35%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 3.82%
  • Quick Ratio: 3.30%
Misc:
  • Average Volume: 987,423 shs.
  • Beta: 1.97
  • Short Ratio: 15.12
 

Frequently Asked Questions for Pacific Biosciences of California (NASDAQ:PACB)

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) announced its earnings results on Wednesday, April, 26th. The company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.03. The firm earned $24.90 million during the quarter, compared to the consensus estimate of $23.80 million. Pacific Biosciences of California had a negative return on equity of 75.50% and a negative net margin of 81.99%. The business's revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. View Pacific Biosciences of California's Earnings History.

When will Pacific Biosciences of California make its next earnings announcement?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Pacific Biosciences of California.

Where is Pacific Biosciences of California's stock going? Where will Pacific Biosciences of California's stock price be in 2017?

3 equities research analysts have issued 12-month target prices for Pacific Biosciences of California's stock. Their predictions range from $8.00 to $12.00. On average, they anticipate Pacific Biosciences of California's stock price to reach $10.33 in the next year. View Analyst Ratings for Pacific Biosciences of California.

What are analysts saying about Pacific Biosciences of California stock?

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:

  • 1. According to Zacks Investment Research, "Pacific Biosciences posted an unimpressive first quarter of fiscal 2017, registering wider-than-expected loss. In the past six months, shares of the company underperformed the broader industry in terms of price. On the brighter side, solid contribution from the Instrument and Consumable revenue platforms is a significant positive. We are also upbeat about the higher margin sales of the SequelTM System. However, headwinds related to the limited availability of SMRT cells (Single Molecule, Real-Time) for the Sequel system and higher non-cash operating expenses are expected to mar prospects over the long haul. Meanwhile, the company witnessed significant strength in China. Notably, it has placed numerous system orders in the region with both new and existing customers." (5/1/2017)
  • 2. Cantor Fitzgerald analysts commented, "Solid 4Q16 results despite lower than-expected Sequel bookings. The company reported total revenues of $25.7M, $2.5M above our estimate of $23.2M and $2.7M above FactSet consensus of $23.0M. System revenue beat due to strong placements in the quarter, slightly offset by lower-than-expected consumable revenue." (2/3/2017)

Who are some of Pacific Biosciences of California's key competitors?

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:

  • Michael W. Hunkapiller Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Susan K. Barnes, Chief Financial Officer, Executive Vice President, Principal Accounting Officer
  • Kevin P. Corcoran, Senior Vice President - Market Development
  • Michael Phillips, Senior Vice President - Research and Development
  • William W. Ericson, Lead Independent Director
  • David Botstein Ph.D., Independent Director
  • Brook H. Byers Ph.D., Independent Director
  • Randall Livingston, Independent Director
  • John F. Milligan Ph.D., Independent Director

Who owns Pacific Biosciences of California stock?

Pacific Biosciences of California's stock is owned by a number of of retail and institutional investors. Top institutional investors include Oracle Investment Management Inc. (5.89%), Raging Capital Management LLC (5.28%), Vanguard Group Inc. (3.90%), Gilder Gagnon Howe & Co. LLC (3.87%), Blackstone Group L.P. (2.58%) and Point72 Asset Management L.P. (1.37%). View Institutional Ownership Trends for Pacific Biosciences of California.

Who sold Pacific Biosciences of California stock? Who is selling Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Mutual of America Capital Management LLC, Goldman Sachs Group Inc., JPMorgan Chase & Co., Credit Suisse AG, IFP Advisors Inc, TIAA CREF Investment Management LLC and ProShare Advisors LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Who bought Pacific Biosciences of California stock? Who is buying Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was acquired by a variety of institutional investors in the last quarter, including Raging Capital Management LLC, Gilder Gagnon Howe & Co. LLC, Point72 Asset Management L.P., Morgan Stanley, Vanguard Group Inc., Stephens Inc. AR, Teachers Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy Pacific Biosciences of California stock?

Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of Pacific Biosciences of California stock can currently be purchased for approximately $3.66.


MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pacific Biosciences of California (NASDAQ:PACB) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $10.33 (182.33% upside)

Analysts' Ratings History for Pacific Biosciences of California (NASDAQ:PACB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00MediumView Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$12.00N/AView Rating Details
6/27/2016CL KingInitiated CoverageBuy$11.00N/AView Rating Details
4/15/2016MKM PartnersInitiated CoverageNeutral$16.50N/AView Rating Details
4/14/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
2/5/2016StephensReiterated RatingBuyN/AView Rating Details
2/4/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$9.00 -> $11.00N/AView Rating Details
10/23/2015William BlairReiterated RatingBuyN/AView Rating Details
8/27/2015Maxim GroupReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Pacific Biosciences of California (NASDAQ:PACB)
Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Earnings History by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
4/26/2017Q1 2017($0.23)($0.26)$23.80 million$24.90 millionViewN/AView Earnings Details
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)$10.17 million$11.64 millionViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pacific Biosciences of California (NASDAQ:PACB)
2017 EPS Consensus Estimate: ($0.89)
2018 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.21)($0.19)($0.20)
Q2 20172($0.26)($0.24)($0.25)
Q3 20172($0.23)($0.22)($0.23)
Q4 20172($0.21)($0.21)($0.21)
Q1 20182($0.20)($0.20)($0.20)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacific Biosciences of California (NASDAQ:PACB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pacific Biosciences of California (NASDAQ:PACB)
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 69.17%
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.00View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.00View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pacific Biosciences of California (NASDAQ:PACB)
Latest Headlines for Pacific Biosciences of California (NASDAQ:PACB)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 6:19 PM
finance.yahoo.com logoRecent Publications Demonstrate Rapid Adoption of SMRT Sequencing for Plant and Animal Transcriptome Analysis
finance.yahoo.com - May 22 at 9:43 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Pacific Biosciences of California's FY2017 Earnings (PACB)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 7:35 PM
finance.yahoo.com logoPacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 11:15 AM
americanbankingnews.com logo-$0.24 Earnings Per Share Expected for Pacific Biosciences of California (PACB) This Quarter
www.americanbankingnews.com - May 5 at 11:20 PM
americanbankingnews.com logoZacks: Analysts Expect Pacific Biosciences of California (PACB) Will Announce Quarterly Sales of $23.27 Million
www.americanbankingnews.com - May 4 at 12:26 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Pacific Biosciences of California (PACB) Reduced by Analyst
www.americanbankingnews.com - May 4 at 11:54 AM
fool.com logoThis Is the Big Reason Behind Pacific Biosciences of California, Inc.'s 24% Tumble in April - Motley Fool
www.fool.com - May 3 at 7:56 PM
finance.yahoo.com logoThis Is the Big Reason Behind Pacific Biosciences of California, Inc.'s 24% Tumble in April
finance.yahoo.com - May 3 at 7:56 PM
americanbankingnews.com logoQ1 2018 Earnings Forecast for Pacific Biosciences of California Issued By William Blair (PACB)
www.americanbankingnews.com - May 3 at 4:42 PM
americanbankingnews.com logoPacific Biosciences of California (PACB) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - May 3 at 4:14 PM
fool.com logoThis Is the Big Reason Behind Pacific Biosciences of California, Inc.'s 24% Tumble in April
www.fool.com - May 3 at 9:58 AM
americanbankingnews.com logoZacks: Brokerages Expect Pacific Biosciences of California (PACB) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - May 2 at 5:56 PM
americanbankingnews.com logoZacks Investment Research Upgrades Pacific Biosciences of California (PACB) to "Hold"
www.americanbankingnews.com - May 1 at 5:18 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Pacific Biosciences of California Decreased by First Analysis (PACB)
www.americanbankingnews.com - May 1 at 7:44 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Earns Coverage Optimism Score of 0.05
www.americanbankingnews.com - April 30 at 4:11 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin Pharmaceutical - Yahoo Finance
finance.yahoo.com - April 29 at 7:32 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin Pharmaceutical
finance.yahoo.com - April 28 at 8:33 AM
finance.yahoo.com logoPacific Biosciences (PACB) Q1 Loss Wider than Estimated - Yahoo Finance
finance.yahoo.com - April 28 at 12:35 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Getting Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 10:34 PM
seekingalpha.com logoPacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 7:34 PM
finance.yahoo.com logoEdited Transcript of PACB earnings conference call or presentation 26-Apr-17 8:30pm GMT
finance.yahoo.com - April 27 at 7:34 PM
americanbankingnews.com logoPacific Biosciences of California (PACB) Given a $8.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 27 at 6:38 PM
fool.com logoHere's Why Pacific Biosciences of California Is Sliding Today
www.fool.com - April 27 at 2:16 PM
fool.com logoPacific Biosciences of California Reports Q1 Loss Due to Higher Costs
www.fool.com - April 27 at 2:16 PM
finance.yahoo.com logoPacific Biosciences (PACB) Q1 Loss Wider than Estimated
finance.yahoo.com - April 27 at 10:22 AM
finance.yahoo.com logoBiotech Movers: Pacific Biosciences Falls After Net Loss Spikes
finance.yahoo.com - April 27 at 10:22 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Announces Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - April 27 at 1:07 AM
rttnews.com logoEARNINGS SUMMARY: Details of Pacific Biosciences of California, Inc. Q1 Earnings Report
www.rttnews.com - April 26 at 6:08 PM
reuters.com logoBRIEF-Pacific Biosciences Of California qtrly loss 26 cents/shr
www.reuters.com - April 26 at 6:08 PM
finance.yahoo.com logoPacific Biosciences of California, Inc. Announces First Quarter 2017 Financial Results
finance.yahoo.com - April 26 at 6:08 PM
marketbeat.com logoPacific Biosciences reports 1Q loss
marketbeat.com - April 26 at 4:20 PM
finance.yahoo.com logoPacific Biosciences of California, Inc. – Value Analysis (NASDAQ:PACB) : April 25, 2017
finance.yahoo.com - April 25 at 6:18 PM
finance.yahoo.com logoPacific Biosciences of California, Inc. breached its 50 day moving average in a Bullish Manner : PACB-US : April 24, 2017
finance.yahoo.com - April 24 at 1:50 PM
americanbankingnews.com logoPacific Biosciences of California (PACB) Getting Somewhat Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 24 at 1:36 PM
americanbankingnews.com logoPacific Biosciences of California (PACB) Short Interest Update
www.americanbankingnews.com - April 24 at 7:10 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Given Coverage Optimism Rating of 0.48
www.americanbankingnews.com - April 18 at 11:56 AM
finance.yahoo.com logoPacific Biosciences (PACB): What Awaits in Q1 Earnings?
finance.yahoo.com - April 17 at 9:39 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 17 at 8:58 AM
americanbankingnews.com logoPositive News Coverage Somewhat Likely to Impact Pacific Biosciences of California (PACB) Share Price
www.americanbankingnews.com - April 15 at 4:51 PM
americanbankingnews.com logoZacks: Brokerages Expect Pacific Biosciences of California (PACB) Will Post Quarterly Sales of $24.66 Million
www.americanbankingnews.com - April 13 at 12:16 PM
americanbankingnews.com logoPacific Biosciences of California (PACB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:44 PM
americanbankingnews.com logoPacific Biosciences of California (PACB) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 11 at 12:26 PM
finance.yahoo.com logoPacific Biosciences of California, Inc. breached its 50 day moving average in a Bearish Manner : PACB-US : April 6, 2017
finance.yahoo.com - April 7 at 11:47 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 12:37 PM
seekingalpha.com logoCowen bullish on growth of next-gen sequencing, says Pac Bio's systems best for small volume work, shares ahead 12%
seekingalpha.com - March 29 at 7:49 PM
fool.com logoPacific Biosciences of California's Recovery Continues
www.fool.com - March 29 at 1:04 PM
seekingalpha.com logoPacific Biosciences Looking More Interesting Once Again
seekingalpha.com - March 26 at 8:13 AM
americanbankingnews.com logoPacific Biosciences of California (PACB) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 23 at 12:46 PM

Social

Chart

Pacific Biosciences of California (PACB) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff